RESMED INC (RMD) Form 8-K — Oct 29, 2026
ResMed reported Q1 fiscal 2027 revenue of $1.415 billion, up 6% year over year (7% on a core constant currency basis), with GAAP diluted EPS of $2.92, up 23%, and non-GAAP diluted EPS of $2.91, up 14%. The company closed its MatrixCare divestiture (net proceeds of $450.8 million) and returned more than $1.0 billion to shareholders in the quarter through $936 million of share repurchases and dividends, while maintaining its full-year guidance of $5.75-$5.85 billion in revenue and $12.00-$12.25 in non-GAAP diluted EPS.
Key figures
- Eps
- 2.92
- Revenue
- 1415000000
- Guidance
- FY2027 core constant currency revenue growth of 5-7%, reported revenue $5.75-$5.85B, non-GAAP diluted EPS $12.00-$12.25 (unchanged from August 6, 2026 guidance)
- Net Income
- 418413000
- Revenue Yoy
- 6%
- Total Assets
- 8211811000
- Cash Position
- 1010742000
- Free cash flow
- 374000000
- Gaap gross margin
- 61.5%
- Prior year revenue
- 1336000000
- Quarterly dividend
- $0.66 per share
- Operating cash flow
- 422000000
- Dividend record date
- November 12, 2026
- Non gaap diluted eps
- $2.91, up 14% YoY
- Dividend payable date
- December 17, 2026
- Non gaap gross margin
- 62.5%, up 50 bps
- Prior year diluted eps
- 2.37
- Shareholder returns q1
- more than $1.0 billion via buybacks and dividends
- Treasury stock purchases
- 936378000
- Non gaap operating margin
- 35.8%
- Matrix Care divestiture proceeds
- 450820000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.